Suppr超能文献

间质干细胞在同种异体或异种移植后在大鼠纹状体中引起弱的免疫反应。

Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation.

机构信息

INSERM UMR 643, Nantes cedex 1, France.

出版信息

J Cell Mol Med. 2009 Aug;13(8B):2547-58. doi: 10.1111/j.1582-4934.2009.00657.x.

Abstract

Mesenchymal stem cells (MSCs) have attracted attention for their potential use in regenerative medicine such as brain transplantation. As MSCs are considered to be hypoimmunogenic, transplanted MSCs should not trigger a strong host inflammatory response. To verify this hypothesis, we studied the brain immune response after transplantation of human or rat MSCs into the rat striatum and MSC fate at days 5, 14, 21 and 63 after transplantation. Flow cytometry analysis indicated that both MSCs express CD90 and human leucocyte antigen (MHC) class I, but no MHC class II molecules. They do not express CD45 or CD34 antigens. However, MSC phenotype varies with passage number. Human MSCs have mRNAs for interleukin (IL)-6, IL-8, IL-12, tumour necrosis factor (TNF)-alpha and TGF-beta(1), whereas rat MSCs express IL-6-, IL-10-, IL-12- and TGF-beta(1)-mRNAs. The quantification shows higher levels of mRNAs for the anti-inflammatory molecules IL-6 and TGF-beta(1) than for pro-inflammatory cytokines IL-8 and IL-12; ELISA analysis showed no IL-12 whereas TGF-beta(1) and IL-6 were detected. Transplant size did not significantly vary between 14 and 63 days after transplantation, indicating an absence of immune rejection of the grafts. Very few mast cells and moderate macrophage and microglial infiltrations, observed at day 5 remained stable until day 63 after transplantation in both rat and human MSC grafts. The observations of very few dendritic cells, T alphabeta-cells, and no T gammadelta-lymphocytes, all three being associated with Tp rejection in the brain, support the contention that MSCs are hypoimmunogenic. Our results suggest that MSCs are of great interest in regenerative medicine in a (xeno)transplantation setting.

摘要

间充质干细胞(MSCs)因其在再生医学中的潜在应用而受到关注,如脑移植。由于 MSCs 被认为是低免疫原性的,因此移植的 MSCs 不应引发强烈的宿主炎症反应。为了验证这一假设,我们研究了将人或大鼠 MSCs 移植到大鼠纹状体后大脑的免疫反应以及移植后 5、14、21 和 63 天 MSC 的命运。流式细胞术分析表明,两种 MSCs 均表达 CD90 和人白细胞抗原(MHC)I 类,但不表达 MHC Ⅱ类分子。它们不表达 CD45 或 CD34 抗原。然而,MSC 表型随传代数而变化。人 MSCs 具有白细胞介素(IL)-6、IL-8、IL-12、肿瘤坏死因子(TNF)-α和 TGF-β(1)的 mRNA,而大鼠 MSCs 表达 IL-6-、IL-10-、IL-12-和 TGF-β(1)的 mRNA。定量分析显示,抗炎分子 IL-6 和 TGF-β(1)的 mRNA 水平高于促炎细胞因子 IL-8 和 IL-12;ELISA 分析未检测到 IL-12,而检测到 TGF-β(1)和 IL-6。移植后 14 天至 63 天,移植体大小无明显差异,表明移植物未发生免疫排斥。在大鼠和人 MSC 移植体中,第 5 天观察到的少量肥大细胞和适度的巨噬细胞和小胶质细胞浸润一直稳定到移植后 63 天。非常少的树突状细胞、T alpha beta-细胞和没有 T gammadelta-淋巴细胞,这三者都与脑 Tp 排斥有关,支持 MSCs 低免疫原性的观点。我们的研究结果表明,MSCs 在(异种)移植背景下的再生医学中具有很大的应用价值。

相似文献

1
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation.
J Cell Mol Med. 2009 Aug;13(8B):2547-58. doi: 10.1111/j.1582-4934.2009.00657.x.
4
Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells.
Clin Exp Immunol. 2014 Jun;176(3):473-84. doi: 10.1111/cei.12283.
6
Rat allogeneic mesenchymal stem cells did not prolong the survival of corneal xenograft in a pig-to-rat model.
Vet Ophthalmol. 2009 Nov-Dec;12 Suppl 1:35-40. doi: 10.1111/j.1463-5224.2009.00724.x.

引用本文的文献

1
Soluble CCR2-Expressing Mesenchymal Stem Cells Inhibit Osteoarthritis Development and Progression.
Immune Netw. 2025 Jun 16;25(3):e24. doi: 10.4110/in.2025.25.e24. eCollection 2025 Jun.
2
Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.
Int J Mol Sci. 2024 Mar 29;25(7):3845. doi: 10.3390/ijms25073845.
5
Factors Defining Human Adipose Stem/Stromal Cell Immunomodulation in Vitro.
Stem Cell Rev Rep. 2024 Jan;20(1):175-205. doi: 10.1007/s12015-023-10654-7. Epub 2023 Nov 14.
6
Retention of Human iPSC-Derived or Primary Cells Following Xenotransplantation into Rat Immune-Privileged Sites.
Bioengineering (Basel). 2023 Sep 6;10(9):1049. doi: 10.3390/bioengineering10091049.
7
Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury.
Mol Ther. 2023 Oct 4;31(10):3067-3083. doi: 10.1016/j.ymthe.2023.07.024. Epub 2023 Aug 2.
8
Influence of type 2 diabetes and obesity on adipose mesenchymal stem/stromal cell immunoregulation.
Cell Tissue Res. 2023 Oct;394(1):33-53. doi: 10.1007/s00441-023-03801-6. Epub 2023 Jul 18.
9
Long noncoding RNA LUCAT1 enhances the survival and therapeutic effects of mesenchymal stromal cells post-myocardial infarction.
Mol Ther Nucleic Acids. 2021 Dec 11;27:412-426. doi: 10.1016/j.omtn.2021.12.006. eCollection 2022 Mar 8.
10
Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus.
Int J Endocrinol. 2021 May 28;2021:9938658. doi: 10.1155/2021/9938658. eCollection 2021.

本文引用的文献

1
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.
Transplantation. 2007 Jan 15;83(1):71-6. doi: 10.1097/01.tp.0000244572.24780.54.
2
Porcine fetal ventral mesencephalic cells are targets for primed xenoreactive human T cells.
Cell Transplant. 2006;15(5):381-7. doi: 10.3727/000000006783981846.
4
Dendritic cell recruitment following xenografting of pig fetal mesencephalic cells into the rat brain.
Exp Neurol. 2006 Nov;202(1):76-84. doi: 10.1016/j.expneurol.2006.05.021. Epub 2006 Jul 7.
8
Human mesenchymal stem cells modulate B-cell functions.
Blood. 2006 Jan 1;107(1):367-72. doi: 10.1182/blood-2005-07-2657. Epub 2005 Sep 1.
9
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.
Exp Cell Res. 2005 Apr 15;305(1):33-41. doi: 10.1016/j.yexcr.2004.12.013. Epub 2005 Jan 25.
10
Immune problems in central nervous system cell therapy.
NeuroRx. 2004 Oct;1(4):472-81. doi: 10.1602/neurorx.1.4.472.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验